<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202601</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI310Y101</org_study_id>
    <nct_id>NCT04202601</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer</brief_title>
  <official_title>Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of sintilimab+ IBI310 for
      EBV-Positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 13, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arms 1: Neoadjuvant therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Pathological complete regression (pCR):
Pathological complete regression (pCR) is defined as the proportion of patients with pathological complete regression (TRG1a) over the total number of patients evaluated centrally by the study pathologist</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arms 2: first-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Objective response rate(ORR):
Objective response rate(ORR) of Sintilimab in combination with IBI310 in all participants in this group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arms 3:≥second-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Objective response rate(ORR):
Objective response rate(ORR) of Sintilimab in combination with IBI310 in all participants in this group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arms 1: Neoadjuvant therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>R0 resection rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1: Neoadjuvant therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Event free survival(EFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1: Neoadjuvant therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Objective response rate(ORR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1: Neoadjuvant therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Disease control rate(DCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1: Neoadjuvant therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Overall survival(OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1: Neoadjuvant therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Number of participants experiencing clinical and laboratory adverse events (AEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 2: first-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Progression-free survival (PFS）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 2: first-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Disease control rate (DCR）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 2: first-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Overall survival (OS）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 2: first-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>( Number of participants experiencing clinical and laboratory adverse events (AEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 3:≥second-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Progression-free survival (PFS）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 3:≥second-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Disease control rate (DCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 3:≥second-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Overall survival (OS）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 3:≥second-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Number of participants experiencing clinical and laboratory adverse events (AEs)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>first-line therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>≥second-line therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Arms 1: Neoadjuvant therapy group 20 patients Drug: Sintilimab Weight&lt;60Kg: 3mg/kg Q3W Weight&gt;=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Perioperative Sintilimab+IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .
Arms 2: first-line therapy group, 30 patients Drug: Sintilimab Weight&lt;60Kg: 3mg/kg Q3W Weight&gt;=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.
Arms 3: ≥second-line therapy group, 30 patients Drug: Sintilimab Weight&lt;60Kg: 3mg/kg Q3W Weight&gt;=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.</description>
    <arm_group_label>Neoadjuvant therapy group</arm_group_label>
    <arm_group_label>first-line therapy group</arm_group_label>
    <arm_group_label>≥second-line therapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI310</intervention_name>
    <description>Arms 1: Neoadjuvant therapy group, 20 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Perioperative Sintilimab+ IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .
Arms 2: first-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.
Arms 3: ≥second-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.</description>
    <arm_group_label>Neoadjuvant therapy group</arm_group_label>
    <arm_group_label>first-line therapy group</arm_group_label>
    <arm_group_label>≥second-line therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has histologically confirmed diagnosis of unresectable locally advanced,recurrent or
             metastatic gastric or GEJ malignant tumor (including squamous carcinoma,
             adenocarcinoma, Signet-ring cell carcinoma).

          -  Confirmed EBV positive determined by in situ hybridization (ISH), analyzed with tumor
             tissue sample, either from a previous surgery or biopsy , within last 6 months

          -  Male or Female at least 18 years of age

          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Has adequate organ function.

          -  Expected survival&gt;=12 weeks

          -  Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy
             test at the timing of enrollment.

          -  Participants of childbearing potential must be willing to use an adequate method of
             contraception for the course of the study through 6 months after the last dose of
             study medication.

        Applied to Arms 1: Has histologically confirmed gastric/GEJ malignant tumor, and were
        regarded as having clinical stage T3-T4aN0M0 or T2～4aN+M0

        Applied to Arms 2: Had no prior systemic treatment for metastatic disease.

        Applied to Arms 3: Received ≥1 prior systemic treatment for metastatic disease.

        Exclusion Criteria:

          -  Has received prior therapy with an anti-programmed death (PD)-1, antiPD-L1, anti-PD
             L2, anti-CTLA-4 agent or with an agent directed to another stimulatory or
             co-inhibitory T-cell receptor

          -  Is currently participating in and receiving study therapy ,except those in the
             survival follow up period of an investigational agent study or non-interventional
             study .

          -  Received systemic treatment with corticosteroids (&gt; 10 mg daily prednisone equivalent)
             or other immunosuppressive medications within 4 weeks of first dose. Inhaled or
             topical steroids ,adrenal replacement steroid doses and steroid of prevention allergic
             reaction of i.v. contrast agent are permitted in the absence of active autoimmune
             disease.

          -  Received a live vaccine within 4 weeks of the first dose of study medication or plan
             to receive live vaccine during study period.

          -  Has had major surgery (craniotomy, thoracotomy or laparotomy) within 4 weeks prior to
             first dose of study medication, or anticipation of the need for major surgery during
             the course of study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lin Shen, professor</last_name>
    <phone>86-10-88196561</phone>
    <email>linshenpku@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhi Peng, Associate Professor</last_name>
    <phone>86-10-88196561</phone>
    <email>zhipeng3@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shen Lin, Professor</last_name>
      <phone>010-88196561</phone>
      <email>Linshenpku@163.com</email>
    </contact>
    <investigator>
      <last_name>Shen Lin, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>MD,Professor,Chief of Department of GI Oncology,Peking University Cancer Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

